Organisation paid for research Program year 2025 Source: CMS Open Payments

Apg Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,979,836

999 payments

Through program year 2025, Apg Research LLC is reported as receiving $4,979,836 in research payments, across 999 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$614,168	151
2024	Research	$612,067	102
2023	Research	$699,352	201
2022	Research	$573,839	136
2021	Research	$811,123	71
2020	Research	$863,680	179
2019	Research	$805,607	159

Breakdown

Who paid Research payments · program years 2019–2025

Janssen Research & Development, LLC $1,293,350 127 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $525,352 20 payments
Genentech, Inc. $517,498 44 payments
ACADIA Pharmaceuticals Inc $498,772 47 payments
ITI, Inc. $443,956 120 payments
AbbVie, Inc. $410,119 98 payments
LivaNova USA, Inc. $243,184 63 payments
F. Hoffmann-La Roche AG $212,684 34 payments
Jazz Pharmaceuticals Inc. $192,803 181 payments
Neurocrine Biosciences, Inc. $175,829 71 payments

Studies the money was for Research payments · program years 2019–2025

A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $673,091 65 payments
Phase III Study of Balovaptan in Adults With Asd $390,062 38 payments
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $388,768 24 payments
Acp-103-069 $300,239 23 payments
V1a 2 in Pediatric Autism $212,684 34 payments
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $185,983 36 payments
Acp-103-070 $183,133 23 payments
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder $168,474 20 payments
A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $161,805 3 payments
Iti-007-321 $136,230 55 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.